OPKO Health (OPK) Stock Overview
Operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OPK Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OPKO Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.20 |
| 52 Week High | US$1.61 |
| 52 Week Low | US$0.98 |
| Beta | 1.48 |
| 1 Month Change | -15.49% |
| 3 Month Change | -1.64% |
| 1 Year Change | -14.29% |
| 3 Year Change | -34.78% |
| 5 Year Change | -66.39% |
| Change since IPO | -73.33% |
Recent News & Updates
Narrative Update • Jul 06
OPK: Share Repurchases And Higher Earnings Multiple Will Shape Future Performance
Analysts have raised their fair value estimate for OPKO Health from $1.30 to $3.00 per share, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E expectations as the key drivers of the new price target range. What’s in the News for OPKO Health OPKO Health issued revenue guidance for the second quarter ending June 30, 2026, projecting total revenue between $127 million and $132 million.
Narrative Update • Jun 22
OPK: Expanded China Partnership Will Drive Future Confidence In Core Business
Analysts have revised their price target for OPKO Health to $8.50 from $8.06, reflecting changes in assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E following recent research, including a downgrade. What’s in the News for OPKO Health OPKO Biologics presented preclinical data for OPK8801001 at ENDO 2026, showing dose dependent and sustained suppression of IGF-1 in models of acromegaly, with approximately 20x greater potency in growth hormone receptor antagonism compared with Pegvisomant, according to conference reports.Analysis Article • Jun 16
OPKO Health (OPK) Stock Could Be 58.8% Undervalued After OPK8801001 Preclinical Update
OPKO Health (OPK) stock is in focus after OPKO Biologics shared preclinical results for its acromegaly candidate OPK8801001, highlighting strong, dose-dependent IGF-1 suppression and higher growth hormone receptor antagonism compared with existing therapy. See our latest analysis for OPKO Health. Following the ENDO 2026 update on OPK8801001, OPKO Health’s 30-day share price return of 27.27% and 90-day gain of 17.65% suggest building momentum. However, the 5-year total shareholder return, down...Narrative Update • Jun 05
OPK: Downgraded Revenue Outlook Will Shape Future Share Performance
Analysts have trimmed their price target on OPKO Health to $1.30, with the change tied to updated assumptions around discount rates, revenue growth, profit margins, and future P/E. These assumptions were cautious enough to support a downgrade in recent research.Recent updates
Narrative Update • Jul 06
OPK: Share Repurchases And Higher Earnings Multiple Will Shape Future Performance
Analysts have raised their fair value estimate for OPKO Health from $1.30 to $3.00 per share, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E expectations as the key drivers of the new price target range. What’s in the News for OPKO Health OPKO Health issued revenue guidance for the second quarter ending June 30, 2026, projecting total revenue between $127 million and $132 million.Narrative Update • Jun 22
OPK: Expanded China Partnership Will Drive Future Confidence In Core Business
Analysts have revised their price target for OPKO Health to $8.50 from $8.06, reflecting changes in assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E following recent research, including a downgrade. What’s in the News for OPKO Health OPKO Biologics presented preclinical data for OPK8801001 at ENDO 2026, showing dose dependent and sustained suppression of IGF-1 in models of acromegaly, with approximately 20x greater potency in growth hormone receptor antagonism compared with Pegvisomant, according to conference reports.Analysis Article • Jun 16
OPKO Health (OPK) Stock Could Be 58.8% Undervalued After OPK8801001 Preclinical Update
OPKO Health (OPK) stock is in focus after OPKO Biologics shared preclinical results for its acromegaly candidate OPK8801001, highlighting strong, dose-dependent IGF-1 suppression and higher growth hormone receptor antagonism compared with existing therapy. See our latest analysis for OPKO Health. Following the ENDO 2026 update on OPK8801001, OPKO Health’s 30-day share price return of 27.27% and 90-day gain of 17.65% suggest building momentum. However, the 5-year total shareholder return, down...Narrative Update • Jun 05
OPK: Downgraded Revenue Outlook Will Shape Future Share Performance
Analysts have trimmed their price target on OPKO Health to $1.30, with the change tied to updated assumptions around discount rates, revenue growth, profit margins, and future P/E. These assumptions were cautious enough to support a downgrade in recent research.Narrative Update • May 21
OPK: Sustainability Of Other Revenue Will Shape Future Share Performance
Narrative Update Overview The analyst price target for OPKO Health has been reduced by $0.75 to $1.50. Analysts cited concern that recent better than expected quarterly results were heavily supported by other revenue that is not viewed as sustainable.
Narrative Update • Apr 23
OPK: Future Share Repurchases And Revenue Mix Shift Will Support Upside Potential
Narrative Update on OPKO Health Analysts have trimmed their price target on OPKO Health to $1.50 from $2.25, pointing to concerns that recent quarterly results relied heavily on "other revenue" that they view as unlikely to be sustainable. Analyst Commentary Recent research reflects a mixed view on OPKO Health, with the reduced price target to $1.50 highlighting questions around the quality of recent results rather than the headline figures alone.Narrative Update • Apr 09
OPK: Recent Earnings Mix Will Support Future Upside From Current Levels
Analysts have lowered their price target on OPKO Health to $1.50 from $2.25, citing concerns that recent quarterly outperformance relied heavily on other revenue that they view as unlikely to be sustained. Analyst Commentary Bearish analysts have responded to the recent quarter by cutting their price target on OPKO Health to $1.50 from $2.25, framing the result as more of a temporary boost than a clear sign of ongoing strength.Narrative Update • Mar 26
OPK: Future Share Repurchases And Revenue Outlook Will Support Upside Potential
Analysts have trimmed their price target for OPKO Health to $1.50 from $2.25, pointing to a lower fair value estimate of $3.40 and concerns that recent quarterly upside was driven by other revenue sources that they do not view as sustainable. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the recent quarter came in better than expected, which they see as evidence that management can still execute against near term expectations.Narrative Update • Mar 12
OPK: Recent Earnings Reset Will Support Future Upside From Current Levels
Analysts have trimmed their price target on OPKO Health to $1.50 from $2.25, reflecting concerns that recent quarterly results relied heavily on other revenue, which they view as unlikely to continue at the same level. Analyst Commentary Bearish analysts are signaling a more cautious stance on OPKO Health after the latest quarterly results, resetting expectations around both earnings quality and future execution.Narrative Update • Feb 25
OPK: Revised Profit Outlook Will Support Future Upside From Current Levels
Analysts have revised their price target on OPKO Health to $1.60, citing updated views on revenue growth, profit margin assumptions, and a lower future P/E of 38.28 that together reshape expectations for the stock's risk and reward profile. Valuation Changes Fair Value: Held steady at $1.60, indicating no change in the base estimate of what the shares may be worth.Narrative Update • Feb 09
OPK: Early Clinical Validation Will Unlock Upside From Neutral Street Stance
Narrative Update Analysts keep their fair value estimate for OPKO Health steady at US$1.60 while modestly adjusting assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects a wait and see stance as they look for clinical validation of the early stage pipeline highlighted in recent research.Seeking Alpha • Jan 27
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts
Summary I believe OPKO Health will end 2026 on a high note. In partnership with Merck, Regeneron, and BARDA, it is developing ModeX's product candidates aimed at treating COVID-19, influenza, solid tumors, and blood cancers, as well as vaccines against EBV. Additionally, OPKO's balance sheet continues to strengthen, with total debt reaching $395.4 million at the end of Q3, down 22.8% year-over-year. Wall Street analysts project that, thanks to OPKO's revenue growth, its P/S ratio will fall to 1.43x in 2030, which, again, indicates that it is trading at a discount. As a result, I believe OPKO Health's risk/reward profile is attractive for long-term investors. Read the full article on Seeking AlphaNarrative Update • Jan 25
OPK: Early Clinical Proof Will Unlock Upside From Current Neutral Reset
Analysts now anchor their OPKO Health view around a US$1.60 price target, down from US$2.00. They cite more cautious Ngenla out year estimates and the need for further clinical validation across the early stage pipeline.Narrative Update • Jan 11
OPK: Early Clinical Proof Will Drive Future Upside From Current Cautious Reset
Narrative Update The analyst price target for OPKO Health has been reduced from US$2.00 to US$1.60. Analysts highlight the early stage of the company’s clinical pipeline and indicate they would like more clarity on future catalysts before taking a stronger view on the shares.Narrative Update • Dec 26
OPK: Future Clinical Validation Will Unlock Upside Despite Near-Term Pipeline Uncertainty
Analysts have trimmed their price target on OPKO Health to $1.60 from $2.00, citing more cautious long term expectations for Ngenla and the company’s still early stage pipeline that requires clearer clinical and catalyst visibility. Analyst Commentary Recent Street commentary reflects a more tempered outlook on OPKO Health, with coverage initiations and rating changes emphasizing execution risk in both the diagnostics and therapeutics franchises.Narrative Update • Dec 12
OPK: Clinical Progress Will Drive Reassessment Despite Near-Term Pipeline And Revenue Uncertainty
Analysts have reduced their price target on OPKO Health from $2.00 to $1.60 per share, reflecting a higher perceived risk profile and weaker long term revenue growth expectations as they await further clinical validation and clearer pipeline catalysts. Analyst Commentary Recent Street research has underscored a more cautious stance on OPKO Health, with coverage initiations and rating changes highlighting execution risk in the pipeline and uncertain visibility on long term growth.Analysis Article • Sep 19
OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up
It's not a stretch to say that OPKO Health, Inc.'s ( NASDAQ:OPK ) price-to-sales (or "P/S") ratio of 1.8x right now...Narrative Update • Aug 06
Core Testing And FDA Approvals Will Strengthen Diagnostics
The consensus price target for OPKO Health has been reduced, primarily reflecting lower revenue growth expectations and a higher discount rate, resulting in a new fair value estimate of $3.62. What's in the News Issued 2025 revenue guidance of $640–$660 million.Analysis Article • May 24
What OPKO Health, Inc.'s (NASDAQ:OPK) P/S Is Not Telling You
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Analysis Article • May 01
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Narrative • Mar 25
Phase 1 Trials With Merck And Pfizer Will Unlock New Opportunities
Progress in ModeX's pipeline and the Merck collaboration could drive growth in the Pharmaceuticals segment with potential revenue impacts from trials and commercialization.Analysis Article • Mar 05
The OPKO Health, Inc. (NASDAQ:OPK) Full-Year Results Are Out And Analysts Have Published New Forecasts
OPKO Health, Inc. ( NASDAQ:OPK ) defied analyst predictions to release its full-year results, which were ahead of...Analysis Article • Jan 14
OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Could Signal Some Risk
It's not a stretch to say that OPKO Health, Inc.'s ( NASDAQ:OPK ) price-to-sales (or "P/S") ratio of 1.4x right now...Analysis Article • Nov 09
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
As you might know, OPKO Health, Inc. ( NASDAQ:OPK ) recently reported its third-quarter numbers. Revenues of US$174m...Seeking Alpha • Aug 28
Not Enough To Keep OPKO Health Flying
Summary OPKO Health's stock is flying high but volatile. The Quant Rating was recently upgraded to Buy, but has been mostly rated Hold or Sell. The company's focus on niche markets and acquisitions poses risks as revenue falls and financial losses mount. We downgraded OPK stock since the pop in the share price to a Sell opportunity. Potential leadership changes could impact the company's direction, but current financial metrics and performance do not justify a significant price rise. Read the full article on Seeking AlphaAnalysis Article • Dec 30
OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar
It's not a stretch to say that OPKO Health, Inc.'s ( NASDAQ:OPK ) price-to-sales (or "P/S") ratio of 1.3x right now...Analysis Article • Oct 03
Is OPKO Health (NASDAQ:OPK) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jul 24
OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Despite an already strong run, OPKO Health, Inc. ( NASDAQ:OPK ) shares have been powering on, with a gain of 28% in the...Shareholder Returns
| OPK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -2.4% | -1.6% | -1.4% |
| 1Y | -14.3% | 39.6% | 17.4% |
Return vs Industry: OPK underperformed the US Healthcare industry which returned 39.6% over the past year.
Return vs Market: OPK underperformed the US Market which returned 17.4% over the past year.
Price Volatility
| OPK volatility | |
|---|---|
| OPK Average Weekly Movement | 6.2% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OPK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OPK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,275 | Phil Frost | www.opko.com |
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system.
OPKO Health, Inc. Fundamentals Summary
| OPK fundamental statistics | |
|---|---|
| Market cap | US$898.56m |
| Earnings (TTM) | -US$212.91m |
| Revenue (TTM) | US$581.12m |
1.6x
P/S Ratio-4.3x
P/E RatioIs OPK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPK income statement (TTM) | |
|---|---|
| Revenue | US$581.12m |
| Cost of Revenue | US$494.44m |
| Gross Profit | US$86.68m |
| Other Expenses | US$299.60m |
| Earnings | -US$212.91m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 14.92% |
| Net Profit Margin | -36.64% |
| Debt/Equity Ratio | 28.7% |
How did OPK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/20 22:58 |
| End of Day Share Price | 2026/07/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OPKO Health, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Louise Chen | Cantor Fitzgerald & Co. |
| Dana Flanders | Guggenheim Securities, LLC |